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1. Introduction
Sarcoidosis is a systemic granulomatous disease of unknown etiology that is characterized
from the point of view of pathology of the presence of noncaseating granulomas in affected
organs. Typically affects young adults and is often present initially with one or more of the
following conditions: 1) bilateral hilar lymphadenopathy, 2) pulmonary reticular pattern, 3)
Involvement of the skin, joints and / or eyes.
In  this  chapter  we  are  going  to  review  and  update  the  clinical  features  and  sign  of
sarcoidosis.
2. Airway involvement
Patients with pulmonary sarcoidosis may have impaired upper and/or lower airway, and
could be impossible or difficult to detect with routine imaging, but are recognized by alterna‐
tive diagnostic tests (eg, bronchoscopy) [1]. Endobronchial disease exists in approximately 40%
of patients with stage I disease, and approximately 70% of patients with stage II or III. Airway
stenosis clinically significant is rare but can be unwieldy when severe [2, 3]. Table 1 summarize
the airway involvement in sarcoidosis.
In the fibrotic stage of the disease can be observed thinning of the mucosa, pallor, and scarring
can lead to a decrease in the light of the airways and the stenosis [4-6].
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Type of involvement Comments
Mucosal erythema and edema Nonspecific finding*
Granular mucosa Nonspecific*
Cobblestone mucosa More common in lobar and segmental bronchi*
Mucosal plaques (yellowish) Also occurs in other disorders*
Mucosal nodules (waxy
yellow)
Characteristic feature*; may occlude bronchi
Bronchial stenosis Lobar and segmental bronchi affected more frequently than central airways;
mucosal biopsy may or may not show granulomas
Airway distortion More likely in advanced parenchymal disease
Bronchiectasis Traction bronchiectasis associated with advanced parenchymal disease; usually
asymptomatic
Bronchiolitis Uncommon; CT scan may suggest diagnosis*
Extrinsic compression Uncommon; may occur with significant thoracic lymphadenopathy
Airway hyperreactivity Occurs in up to 20% of sarcoid patients; endobronchial involvement increases the
risk
Airflow limitation
(FEV1/FVC ratio < 80)
Occurs in 60% of sarcoid patients; seen in any stage
Hemoptysis Uncommon from airway involvement
Obstructive sleep apnea Due to laryngeal involvement; more common in patients with lupus pernio
Supraglottic structures Oral, nasal, and pharyngeal mucosal changes as noted above, hoarseness,
dysphagia, laryngeal paralysis, and airway obstruction
*A biopsy required to document the presence of a noncaseous granuloma; in other types of involvement, a biopsy
specimen may or may not demonstrate noncaseous granulomas.
Modified from Ref. 1
Table 1. Airway involvement in sarcoidosis
2.1. Supraglottic airways
Nasal passages, oropharynx, supraglottic structures, and the larynx develop sarcoid granulo‐
mas in approximately 6% of patients with sarcoidosis [7-10]. Debería sospecharse en todos los
pacientes con sarcoidosis sistémica y síntomas de vía aérea superior [4, 5, 8, 11-12]. Sarcoid
lesions can occur in nasal and oral mucosa, occasionally with ulceration; anosmia improves
after steroid therapy [13]. A nasal examination may reveal granulomatous mass, yellow-white
mucosal papules, and adhesions and crusting of septal and turbinate mucosa. Nodular
sarcoidosis of supraglottic and glottic structures can lead to dyspnea, stridor, dysphonia,
irritating cough with pharyngolaryngeal discomfort, dysphagia, retronasal obstruction,
and/or hyponasal speech. Rhinopharyngolaryngeal endoscopy may reveal reddish or yellow
granulomatous lesions (2-4 mm in diameter) [14]. Laryngoscopy may show epiglottic thick‐
ening and granularity, granulomatous mass and infiltrative sarcoid nodules of epiglottis,
aryepiglottic folds, and false cords. These may cause respiratory distress, requiring tracheos‐
tomy [15]. Flow-volume curves and laryngeal examination are helpful in the diagnosis and
management [16]. Obstructing polypoid sarcoid lesions have been managed with laryngo‐
scopic resection, tracheostomy, or local injection of a corticosteroid [17].
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Obstructive sleep apnea, which occurs in about 5% of the general population, seems to occur
with increased frequency in patients with sarcoidosis, especially in patients with lupus pernio
[18]. Sarcoidosis of the upper airways has been suggested as one of the possible mechanisms
for sleep apnea in patients with sarcoidosis and lupus pernio, although the overwhelming
majority of obstructive sleep apnea in sarcoidosis is most probably related to obesity from
corticosteroids. Sarcoidosis of the supraglottic airways in children is rare [19].
2.2. Larynx
Laryngeal sarcoidosis often occurs as an isolated phenomenon and is usually attributed to
asthma [20]. Occasionally, laryngeal sarcoid can lead to progressive life-threatening airway
obstruction [15]. Laryngeal sarcoidosis is uncommon [21]. The incidence of laryngeal sarcoi‐
dosis is estimated to be about 1.2%. Laryngeal sarcoidosis could be treated with systemic and
intralesional injections of a corticosteroid, surgical intervention, carbon dioxide laser ablation,
and external beam radiation [22, 23].
Paralysis of the left vocal cord and hoarseness can occur from compression of the left recurrent
laryngeal nerve by enlarged lymph nodes [24, 25]. Systemic corticosteroid therapy has resulted
in resolution of the hoarseness [24].
2.3. Central airways
The trachea and main bronchi are less frequently affected than the lobar, segmental, subseg‐
mental, and distal airways. Sarcoid granulomas of trachea, main carina, and major bronchi by
themselves seldom produce significant obstructive symptoms or airway dysfunction [26, 27].
Cough is the main symptom. Symptoms, clinical examination, flow-volume curves, and
bronchoscopy help in assessing the severity of the central airway stenosis [28].
Mainstem bronchial stenoses as well as segmental stenosis have been described in patients
with sarcoidosis [29]. Disabling inspiratory and expiratory airflow limitation mimicking fixed
upper airway obstruction has been reported [27]. Bronchoscopy may demonstrate other
changes as: mucosal erythema, edema, friability, granularity, fine cobblestoning, and sarcoid
nodules. The characteristic yellow waxy nodules typical of sarcoidosis are less likely to occur
in the trachea and main bronchi, but when seen in these areas, they tend to be sparsely
distributed.
Extrinsic compression of the central airways by the enlarged mediastinal and hilar lymph
nodes is uncommon. Right middle lobe syndrome caused by extrinsic compression and
intraluminal sarcoidosis has been described [30].
2.4. Distal airways
Sarcoidosis could affect lobar, segmental, subsegmental, and more distal bronchi as well as
bronchioles, which is manifested as mucosal inflammation, endobronchial granulomas,
stenosis, extrinsic compression, distortion, bronchiectasis, bronchiolitis, airway hyperreactiv‐
ity, and streaky hemoptysis.
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These can lead to airway dysfunction and respiratory symptoms. Sarcoid granulomas tend to
develop along the bronchovascular bundle or in the vicinity of the airways. All of these changes
are more likely to affect the airways in upper and mid-lung regions.
The various types of airway abnormalities encountered in patients with sarcoidosis are
described in the following paragraphs.
a. Endobronchial Granulomas
The definitive diagnosis of endobronchial granulomata requires a biopsy of the airway mucosa
because a normal-appearing airway mucosa does not exclude the presence of granulomas [31].
The mucosal abnormalities can be diffuse or patchy. These findings are nonspecific and may
be seen in other disorders. Therefore, biopsies of the mucosa and submucosa are essential for
making a histologic diagnosis. Segmental and lobar bronchial lumen can be compromised by
extrinsic compression by an enlarged adjacent lymph node. Endobronchial characteristics of
sarcoid granulomas are well documented [32]. The classic endobronchial sarcoidosis is
characterized by mucosal islands of waxy yellow mucosal nodules, measuring 2 to 4 mm in
diameter. These nodules appear dull gray or waxy yellow. The mucosal lesions tend to be
diffuse but more profuse in the lobar and segmental bronchi. Bronchial luminal occlusion by
sarcoid granulomas can mimic an obstructing malignant mass. Endobronchial granulomas
produce cough, wheezing, and dyspnea. The mucosal nodules seldom ulcerate or bleed.
b. Bronchial Stenosis
Bronchial stenosis is reported to occur in up to 14% of patients with sarcoidosis [33]. Bron‐
choscopy is helpful in evaluating the location, types, and severity of bronchial stenosis. The
stenoses can be solitary or multiple, lobar or segmental bronchial stenoses, with or without
atelectasis, and they may occur at any stage of respiratory sarcoidosis [33-35]. Extensive and
multiple stenotic lesions of larger bronchi may cause or contribute to pulmonary symptoms.
c. Bronchiolitis
Bronchiolar involvement from sarcoidosis can also occur in early sarcoidosis without pulmo‐
nary parenchymal involvement [36, 37]. Bronchiolitis obliterans organizing pneumonia,
bronchiolar narrowing and occlusion, and sarcoidosis coexisting with asthma have been
described [38, 39]. Airtrapping is a common feature in sarcoidosis and correlates with evidence
of small airways disease on pulmonary function testing.
d. Airway Distortion
Airway distortion is common in later stages of sarcoidosis and is caused by granulomatous
changes in and around the airways and the secondary traction bronchiectasis associated with
pulmonary parenchymal fibrosis [40, 41].
e. Bronchiectasis
Traction bronchiectasis becomes evident as the parenchymal disease progresses [40]. Traction
bronchiectasis has been reported in up to 40% of patients with fibrotic stages of sarcoid [41].
Localized bronchiectasis of the right middle lobe caused by obstructing sarcoid granuloma has
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been described [42]. Traction bronchiectasis and bronchial distortion, as described earlier,
seldom cause bronchiectatic symptoms [43].
f. Hemoptysis
Hemoptysis in patients with sarcoidosis is usually the result of a complication such as the
development of an aspergilloma in advanced fibrotic and cavitary sarcoid [44-46]. Large
pulmonary cystic lesions occur in advanced stages of sarcoidosis, and these could potentially
become infected with Aspergillus and aspergilloma could develop. Fatal massive hemoptysis
has been described in such patients [46]. Traction bronchiectasis is observed in patients with
advanced sarcoidosis and endobronchial sarcoidosis rarely causes hemoptysis.
g. Airway Hyperreactivity
Airway hyperreactivity has been reported in up to 20% of patients with sarcoidosis, and, as a
result, cough and wheezing may prompt patients to seek medical help [47, 48]. The airway
hyperreactivity is also responsible for the cough, wheezing, and dyspnea and is independent
of the airway involvement. Airway hyperreactivity in patients with sarcoidosis remains a
difficult entity to define because of the airway involvement by sarcoidosis. The smaller baseline
diameter of the diseased airway can potentially increase airway resistance and lead to a false-
positive bronchoprovocation test result.
2.5. Bronchoscopy
Bronchoscopy plays a significant role in the diagnosis and management of airway sarcoidosis.
The role of the technique in the retrieval of immune effector cells and infectious organisms by
analyzing bronchoalveolar lavage (BAL) fluid, biopsy specimens of pulmonary parenchymal
sarcoid, and needle aspiration/biopsy samples of enlarged lymph nodes in the mediastinum
and hilar regions is well known [49]. These bronchoscopic techniques have an important role
in the diagnosis of infectious diseases in sarcoid patients in whom complications such as
aspergilloma and other infections develop. Bronchoscopy also helps in excluding disorders
that may resemble sarcoidosis.
Bronchoscopic abnormalities have been observed in up to 60% of patients with sarcoidosis [48].
These include “retinalization” of mucosa from increased mucosal vascularity, mucosal
coarseness, pallor, flat yellow mucosal plaques, wartlike excrescences, “bleb-like” formations,
irregular mucosal thickening, ulceration, and atrophic mucosa. The three common findings
were bronchial mucosal hyperemia or edema, distortion of the bronchial anatomy, and
bronchial narrowing. The classic endobronchial sarcoidosis is mucosal islands of waxy yellow
mucosal nodules, 2 to 4 mm in diameter. Bronchoscopy may reveal endobronchial occlusion
by sarcoid granulomas in the submucosa or an endobronchial polyp caused by sarcoid
granulomas [35].
Bronchoscopic biopsy of endobronchial lesions confirms the diagnosis of endobronchial
sarcoidosis in up to 70% patients with the disease [48, 50, 51]. Patients with abnormal-
appearing airways are much more likely to have positive results, with a diagnostic yield of
75% [48]. Even when the airway mucosa appears normal, mucosal biopsy specimens may
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demonstrate mucosal or submucosal noncaseous granulomas in up to 50% of patients with
sarcoidosis [48]. In typical cases, the identification of noncaseous granulomas on frozen section
analysis may render lung biopsy unnecessary.
3. Lung disease
Sarcoidosis occurs in patients aged between 10-40 years in 70-90% of cases. In about half the
cases the disease is detected incidentally by alterations in the chest radiograph. The organ most
frequently affected is the lung. The most common symptoms are cough, dyspnea and chest
pain. In patients in the eighth decade of life is more common than systemic symptoms such as
fatigue and anorexia, although dyspnea is often present at the same time [52].
A pulmonary auscultation crackles or roncus uncommon to hear, but wheezing may be
present.
3.1. Pulmonary imaging
Pulmonary involvement occurs in 90% of patients with sarcoidosis [10]. The typical chest
radiograph shows bilateral hilar lymphadenopathy. This finding, however, may be absent, or
if present may occur in combination with opacities in the parenchyma. Parenchymal opacities
may be interstitial, alveolar or both. Pleural involvement is uncommon (<5%), but may occur
as lymphocytic exudate in the pleural effusion, chylothorax, hemothorax, or pneumothorax
[54-56].
a. Chest x-ray:
Stage of lung involvement is established based on chest radiography. Although the chest
radiograph provides an anatomical guide of lung disease can not measure disease activity or
functional damage assessment. The sarcoid nodule is defined as pulmonary nodules, bilateral
and multiple in the chest radiograph, which may mimic metastatic disease. When viewed
through the computerized tomography (CT) revealed a nodular consolidation with well
defined borders [56]. Radiological stages are (Figure 1):
• Stage I: is defined as the presence of bilateral hilar lymphadenopathy, which are often
accompanied with an increase in right paratracheal adenopathy. 50% of patients initially
present as bilateral hilar lymphadenopathy. In 75% of cases, hilar lymphadenopathy return
within the first through third year, while 10% will persist for 10 years or more.
• Stage II: Defined as bilateral hilar lymphadenopathy and reticular opacities (the latter occurs
more often in the upper lobes). These findings are initially in 25% of patients. In two thirds
of these cases the lesions regress spontaneously, while the rest can be progression of the
disease or remain unchanged over time. Normally the stage II patients have mild or
moderate. The most common symptoms are usually: cough, dyspnea, fever, and/or fatigue.
• Stage III: This is defined as reticular opacities without hilar lymphadenopathy. Reticular
opacities are distributed predominantly in the upper lobes.
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• Stage IV: Is characterized by reticular opacities with evidence of volume loss, chiefly
distributed in the upper lobes. Can also be observed: adenopathic clusters with marked
traction bronchiectasis, or extensive calcification, cavitation or cyst formation [57].
Figure 1. Staging of sarcoidosis on basis of chest radiographs
b. Computerized Axial Tomography (CT) scan:
Sarcoidosis patient can show a variety of abnormalities [58, 59]: Hilar and mediastinal
lymphadenopathy, beaded or irregular thickening of the bronchovascular bundles, nodules
along bronchi, vessels, and subpleural regions, bronchial wall thickening, ground glass
opacification, parenchymal masses or consolidation, parenchymal bands, cysts, traction
bronchiectasis, fibrosis with distortion of the lung architecture.
High-resolution CT has proved superior to conventional CT for assessing subtle parenchymal
details and discriminating between inflammation and fibrosis in patients with pulmonary
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sarcoidosis [58, 60]. The thin-section collimation (1- to 1.5- mm section thickness) and high-
spatial-frequency reconstruction algorithms that are used to generate high-resolution CT
images allow improved detection of nodular and reticular opacities, thickened interlobular
septa, and faint ground-glass opacities, making the technique especially useful for identifying
and managing sarcoidosis.
High-resolution CT may be particularly helpful for distinguishing active inflammation from
irreversible fibrosis in selected patients with stage 2 or 3 sarcoidosis. Nodules, ground-glass
opacities, and alveolar opacities are suggestive of granulomatous inflammation that may be
reversed with therapy [61]. By contrast, honeycomb-like cysts, bullae, broad and coarse septal
bands, architectural distortion, volume loss, and traction bronchiectasis are indicative of
irreversible fibrosis [62]. High-resolution CT may be useful also for verifying specific diagnoses
in patients with atypical clinical manifestations or unusual radiographic features [63].
In the appropriate clinical context, the observation of typical imaging features of sarcoidosis
(eg, bilateral hilar lymph node enlargement with a perilymphatic micronodular pattern) and
the anatomic distribution of those abnormalities (eg, upper lobe predominance) may point to
a highly specific diagnosis. However, atypical manifestations may necessitate a broader
differential diagnosis that includes tuberculosis and other granulomatous infections, silicosis,
malignancies, and pneumoconiosis.
We are going to explain some typical patterns of sarcoidosis. Criado et al. [64] published and
extensive review about typical and typical patterns of sarcoidosis. Table 2 shows typical and
atypical features of pulmonary sarcoidosis at high-resolution CT.
Typical features Atypical features
Lymphadenopathy: hilar, mediastinal (right
paratracheal), bilateral, symmetric, and well defined
Lymphadenopathy: unilateral, isolated, anterior and
posterior mediastinal
Nodules: micronodules (2–4 mm in diameter; well
defined, bilateral); macronodules (≥5 mm in diameter,
coalescing)
Airspace consolidation: masslike opacities,
conglomerate masses, solitary pulmonary nodules,
confluent alveolar opacities (alveolar sarcoid pattern)
Lymphangitic spread: peribronchovascular, subpleural,
interlobular septal
Linear opacities: interlobular septal thickening,
intralobular linear opacities
Fibrotic changes: reticular opacities, architectural
distortion, traction bronchiectasis, bronchio-lectasis,
volume loss
Fibrocystic changes: cysts, bullae, blebs, emphysema,
honeycomb-like opacities with upper- and middle-zone
predominance
Bilateral perihilar opacities Ground-glass opacities
Predominant upper- and middle-zone locations of
parenchymal abnormalities
Miliary opacities
Airway involvement: mosaic attenuation pattern,
tracheobronchial abnormalities, atelectasis
Pleural disease: effusion, chylothorax, hemothorax,
pneumothorax, pleural thickening, calcification
Mycetoma, aspergilloma
Table 2. Typical and Atypical Features of Pulmonary Sarcoidosis at High-Resolution CT. Modified from ref. 64.
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• Typical Patterns of Lymphadenopathy
The most common pattern is well-defined, bilateral, symmetric hilar and right paratracheal
lymph node enlargement. Bilateral hilar lymph node enlargement, alone or in combination
with mediastinal lymph node enlargement, occurs in an estimated 95% of patients affected
with sarcoidosis [65, 66]. Middle mediastinal nodes (at the left paratracheal level, subcarinal
level, and level of the aortopulmonary window), prevascular nodes, or both are involved in
approximately 50% of patients [60].
Bilateral hilar lymph node enlargement may be a feature of infection (particularly fungal or
mycobacterial infection) or malignancy (eg, lymphoma). However, in the absence of specific
symptoms or signs, sarcoidosis is the most common cause of bilateral lymph node enlarge‐
ment. Histologic confirmation is not required for a diagnosis of sarcoidosis in these patients.
However, a biopsy should be performed if the chest radiographic findings worsen or specific
signs and symptoms develop [67].
• Typical Parenchymal Manifestations
1. Micronodules with a Perilymphatic Distribution
A perilymphatic distribution of micronodular lesions is the most common parenchymal disease
pattern seen in patients with pulmonary sarcoidosis (75%–90% of cases). High-resolution CT
shows sharply defined, small (2–4 mm in diameter), rounded nodules, usually with a bilateral
and symmetric distribution, predominantly but not invariably in the upper and middle zones.
The nodules are found most often in the subpleural peribronchovascular interstitium and less
often in the interlobular septa. Although sarcoid granulomas arise as micronodular lesions, they
may coalesce over time, forming larger lesions (macronodules) [56, 58, 63].
Sarcoid granulomas frequently cause nodular or irregular thickening of the peribronchovas‐
cular interstitium. Extensive peribronchovascular nodularity on high-resolution CT images is
strongly suggestive of sarcoidosis. However, interstitial thickening is not extensive in most
patients with sarcoidosis.
2. Fibrotic Changes
In most patients, sarcoid granulomas resolve with time. However, in an estimated 20% of
patients, fibrosis becomes more prominent over time, producing CT and radiographic findings
of linear opacities, traction bronchiectasis, and architectural distortion (displacement of
fissures and bronchovascular bundles). Fibrosis is seen predominantly in the upper and
middle zones, in a patchy distribution [41].
Extensive interstitial fibrosis can cause pulmonary arterial hypertension and resultant right
heart failure. Imaging findings that may be predictive of such an event include a prominent
main pulmonary artery, enlarged right and left pulmonary arteries, right ventricular enlarge‐
ment, and attenuation of peripheral vessels.
3. Bilateral Perihilar Opacities
Confluent nodular opacities that appear on high-resolution CT images as bilateral areas of
lung consolidation with irregular edges and blurred margins, radiating from the hilum toward
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the periphery, are often seen with or without air bronchograms. These areas of consolidation
are less homogeneous peripherally and are usually accompanied by micronodules [41, 60].
c. Positron emission tomography (PET):
A PET fluorine-18-fluorodeoxyglucose (18F-FDG) can help identify occult lesions and poten‐
tially reversible granulomatous disease [69, 70]. This test does not differentiate sarcoidosis
from malignant lesions, as 18F-FDG PET can be positive in both processes. However, in a small
study of 24 sarcoidosis and 17 lung cancer, the combination of 18F-FDG and 18F-FMT (L-
[3-18F]-methyltyrosine) PET scanning was able to differentiate sarcoidosis cancer. Sarcoid
lesions were positive in 18 F-FDG PET but negative on 18 F-FMT PET, and both were positive
for cancer patients [71]. More studies are needed to confirm these findings. Besides the latter
tracer may not be available in all centers.
d. Radiotracer scanning - Gallium-67 lung scanning:
Is a noninvasive test for staging the "alveolitis" found in interstitial lung diseases. This
compound located the site of inflammation of the lung [72-74]. The role of gallium-67 scanning
in the diagnosis and management of sarcoidosis is currently controversial [75]. It has been
suggested that there is a direct relationship between a visual index of gallium-67 uptake in the
lung and the number of inflammatory cells (particularly macrophages) obtained from
bronchoalveolar lavage in patients with sarcoidosis (and idiopathic pulmonary fibrosis). As a
result the uptake of gallium-67 may be useful to determine the degree of alveolar inflammation,
which will focus more lower alveolar macrophages and neutrophils [72-74].
Unfortunately there has not been adequate study to make any correlation of the gallium-67
level with the stage of swelling or how the level of radionuclide uptake may correspond to the
stage of disease. Furthermore, studies in normal subjects demonstrate that there may be a small
but significant uptake of gallium-67 in alveolar macrophages obtained by bronchoalveolar
lavage despite negative imaging test [76].
As a result, actually is not recommended for routine evaluation with gallium-67 lung scanning
in these patients because of the difficulty of interpretation, since it is not specific, and that a
negative test does not exclude the disease.
Other types of radiotracer-based scanning may help in future diagnosis and clinical manage‐
ment of patients with sarcoidosis [77, 78]. As an example, one study of 22 patients with
sarcoidosis scans performed after administration of technetium-labeled Depreotide, which
binds to somatostatin receptors [77]. The scan was positive in 18 patients (81%) and in 4 of
whom was negative had a normal chest radiograph. The features of this test are still unknown,
and clinical use is experimental.
3.2. Pulmonary function test
Characteristically, pulmonary function tests show a restrictive pattern with reduced diffusing
capacity for carbon monoxide. Yet we must bear in mind that pulmonary function tests may
be normal [79]. Endobronchial sarcoidosis may show involvement of airflow obstruction and
respiratory pattern.
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The greatest value of pulmonary function tests is to verify the course of the disease individually
by sequential measurements. Mean it will not detect pulmonary sarcoidosis or provide a
reliable estimate of the extent of parenchymal disease. In addition, the clinician can not predict
the natural course of lung disease or response to treatment based solely on these tests.
3.3. Bronchoalveolar Lavage (BAL)
BAL can be used as an adjuvant as to support the diagnosis of sarcoidosis, showing a reduced
number of CD8 cells, an elevated CD4/CD8 ratio and an increase in activated T cells, CD4,
immunoglobulins, and IgG-secreting cells [80-83]. BAL may also be useful to exclude infections
as an alternative diagnosis.
Lymphocytosis in BAL is neither sensitive nor specific for the diagnosis of sarcoidosis. In
addition, this test can be misinterpreted [80].
The D-dimer in BAL also supports the diagnosis of sarcoidosis. An observational study found
that 8 of the 10 patients with sarcoidosis had detectable D-dimer in the BAL (defined as D-
dimer> 78ng) Compared to none of 18 healthy controls [82]. Among patients with sarcoidosis
are more likely to have a higher D-dimer black patients than whites [83].
3.4. Histopathology
The morphological feature of sarcoidosis is the noncaseating granuloma of the lung, which is
most often found in the alveolar septa, the walls of the bronchi and pulmonary arteries and
veins. Sarcoid granuloma formation probably is preceded by alveolitis which involves more
than the interstitium and alveolar spaces is characterized by the accumulation of inflammatory
cells, including monocytes, macrophages and lymphocytes [84, 85].
The sarcoid granuloma is a chronic inflammatory reaction and focal accumulation formed by
epithelial cells, monocytes, lymphocytes, macrophages and fibroblasts. Multinucleated giant
cells are frequently found between epithelial cells in the follicle of the granuloma and often
have cytoplasmic inclusions such as asteroid bodies, Schaumann bodies and birefringent
crystalline particles (calcium oxalate and other calcium salts) [86]. Most sarcoid granulomas
gradually resolved and leave little or no residual manifestation of prior inflammation.
3.5. Allocation pulmonary vs. extrapulmonary
Health status is a subjective parameter that is being used more frequently to assess health
interventions. Questionnaires have been developed, both generic and disease-specific, to
assess health status. Differences in patients reported outcomes between sarcoidosis patients
with isolated pulmonary involvement and those with extrapulmonary manifestations have
not been well described. In this way, Gvozdenovic et al. [68] develop a study to assess the
differences of the severity of fatigue and dyspnea symptoms, activities of daily living and
health status between the patients with isolated pulmonary and those with pulmonary plus
extrapulmonary sarcoidosis. This study concluded that patients with pulmonary and extrap‐
ulmonary sarcoidosis are more fatigued, have more dyspnea, are more limited in their
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everyday physical activities, and have lower health status in comparison with those with
isolated pulmonary involvement. They proposed several mechanisms to explain these
differences, although remained conjectural and are potential fruitful areas for future research.
4. Pulmonary hypertension complicating sarcoidosis
Pulmonary hypertension (PH) is defined as the presence of a mean pulmonary artery pressure
(mPAP) ≥ 25 mm Hg [87]. Although in most cases sarcoidosis is a disease with good prognosis,
the presence of PH is a serious complication that occurs in cases with severe pulmonary
involvement, although there have been cases of PH in any stages of the disease. An early
diagnosis that may consider different treatment options is critical to improve the prognosis of
these patients.
The prevalence of pulmonary hypertension (SAPH) asociated to sarcoidosis is unknown.
Prospective and retrospective studies describe prevalence from 5 to 28% [88] (see Table 3). This
variability is mainly due to the use of different diagnostic methods, non-homogeneous patient
populations and stages of the disease included in those studies. It has been described that in
patients with mild lung disease in which PH is defined as that PAP ≥ 40 mm Hg measured by
transthoracic echocardiography (TTE), the prevalence is 5.7% [89].
Author/reference Population Number Method Prevalence (%)
Handa (89) Prospective study of unselected patients 212 TTE 5.7
Baughmann (88) Subjects with dyspnea out of proportion 53 RHC 47
Sulica (98) Retrospective study of TTE 106 TTE 51
Table 3. Ascertained prevalence of Sarcoidosis-associated pulmonary hypertension in several populations
A retrospective study of 53 patients with sarcoidosis and persistent dyspnea showed that in
47% of them had a mPAP ≥ 25 mm Hg. Only 69% of these cases had stage 3-4 of sarcoidosis [90].
4.1. Pathophysiology
According to Dana Point classification [91] of pulmonary hypertension, the group 3 includes
cases of PH due to lung disease or hypoxia (including interstitial lung disease). The group 5
includes the cases where PH has not a clarified mechanism; group 5 also includes sarcoidosis
because the pathogenesis of SAPH is associated with complex mechanisms.
a. Destruction of the distal capillary bed
Most patients with sarcoidosis and PH are in advanced stages, presenting a significant
alteration of lung parenchyma with destruction of the capillary bed and leading of hypoxemia.
However, there are cases of SAPH with minimal lung disorder (Stages 0-1) and hemodynamic
measurements detected in the right heart catheterization (RHC) are not always correlated
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directly with lung function or PaO2 [92]. When comparing cases of idiopathic pulmonary
fibrosis and sarcoidosis there are differences in mPAP of 9 mm Hg for an equivalent functional
alteration, so this mechanism does not explain the development of PH in all the patients.
b. Increased vasoreactivity
Few years ago was found that production of endothelin 1 (ET-1) in the lung of patients with
sarcoidosis is increased [93]. The ET-1 is a potent vasoconstrictor with mitogenic and inflam‐
matory activity and one of the therapeutic targets for the treatment of PH, using receptor
antagonists of ET-1. The synthesis and release of nitric oxide (NO) by endothelial cells causes
vasodilatation, the decreased of NO production has been associated with PH. Has been
suggested that the decrease of NO, found in some studies of patient with sarcoidosis, may
participate in the development of SAPH and that could have therapeutic implications [94].
c. Extrinsic compression of pulmonary vessels
There is extrinsic compression of major pulmonary arteries by adenopathies up to 21.4% of
patients with SAPH and pulmonary fibrosis [95]. This alteration is often seen in cases with
mediastinal and bilateral hilIar adenopathies. Compression of the pulmonary vasculature can
also be found in cases of mediastinal fibrosis.
d. Vasculopathy
Granulomatous involvement of the pulmonary vessel occurs in 69-100% of the cases studied
by lung biopsy specimens. Exits occlusive or destructive granulomas or the patient may
develop a perivascular fibrosis. These findings are more frequent in small veins [96].
e. Post-capillary pulmonary hypertension
We mustn`t forget that myocardial involvement in sarcoidosis occurs in up to 5% of cases and
cause ventricular systolic or diastolic failure which contribute to the development of PH [97].
However, the symptomatic myocardial abnormality is lower than that found in necropsy
studies. We can conclude that the mechanisms involved in the development of PH in sarcoi‐
dosis are multiple, involving various anatomical structures and with different therapeutic
implications.
4.2. Clinical presentation
The diagnosis of PH in sarcoidosis is difficult because the most common symptom is dyspnea,
and many times, this symptom is attributed to the presence of parenchymal involvement. The
PH should be suspected in patients with sarcoidosis and dyspnea, hypoxemia, or clinical
evidence of the presence of right heart failure, particularly, if these symptoms have not a
proportional relationship to the degree of parenchymal involvement. Symptoms of right heart
failure are independent predictors of increased pressure in the right cavities. However, these
symptoms have low sensitivity, and are only manifested in 21% of patients with confirmed
PH. The symptoms are: progressive dyspnea, cough, chest pain, palpitations or syncope [98].
Table 4 shows the distribution of the symptoms.
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Sudden death caused by compression of large pulmonary arteries, occlusion of the pulmonary
veins by a sarcoid involvement intravascular or combination of SAPH and portal hypertension
is infrequent.
Symptoms Frequency %
Dyspnea on exertion 85
Cough 36
Chest pain 10
Palpitations 10
Asymptomatic 8
Table 4. Presenting symptoms in Sarcoidosis-associated pulmonary hypertension
4.3. Diagnosis
Patients with SAPH usually present with restrictive dysfunction on pulmonary function tests,
and decrease in carbón monoxide diffusion capacity (DLCO) out of proportion to the decrease
in total lung capacity (TLC). Forced vital capacity (FVC), forced expiratory volumen in 1 second
(FEV1) and DLCO have been reported to be significantly lower in patients with Sarcoidosis
and PH when compared with patients without PH [99].La hipoxemia esta frecuentemente
presente en los pacientes con SAPH siendo este grupo uno de los que con probabilidad va a
requerir oxigeno suplementario y por otra parte recorren menos metros en el 6-minute walking
test cuando se comparan con pacientes que tienen Sarcoidosis en el mismo estadio radiológico
pero sin PH [99].
Transthoracic echocardiography (TTE) represents a noninvasive screening method to evaluate
the presence of PH in sarcoidosis. It is helpful to describe other potential cardiac abnormalities,
such as left heart disease, presence of shunts or pericardial effusion, and to evaluate the right
heart anatomically and functionally. Echocardiography may be used to estimate the right
ventricular systolic pressure (RVSP) if a tricuspid regurgitation jet is present. Echocardio‐
graphically estimated RVSP had inadequate positive and negative predictive value in diag‐
nosing PH in advanced lung disease, so it´s a screening test that cannot supplant right heart
cathetetization (RHC) for the SAPH diagnosis.
RHC is the diagnostic gold standard for SAPH. TTE was unable to detect RVSP in 30% of
the patients and 24% of the patients with elevated PAP had a pulmonary capillary wedge
pressure (PCWP) in excess of 20 mm Hg, underscoring the importance of left ventricular
disease  in  the  pathogenesis  of  PH  in  some  Sarcoidosis  patients.  RHC  should  be  per‐
formed in all cases in which SAPH is suspected or when echocardiography is suggestive
of right heart pathology.
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5. Cardiac sarcoidosis
5.1. Epidemiology
The presence of cardiac sarcoidosis is influenced by race. Over 25% of Japanese sarcoidosis
patients present cardiac disease, only 5% of patients in the United States and Europe are
affected at this level. Although clinical evidence of myocardial involvement is present in 5%
of patients, there are autopsy studies that indicate that sublinical cardiac disease is present in
20-30% of cases.
5.2. Clinical manifestations
Cardiac Sarcoidosis can be an incidental finding, has a benign course or being a life-threatening
disorder. Clinicians should suspect this disease in young or middle-aged patients with cardiac
symptoms and in any patients with a history of sarcoidosis who develop arrhythmias,
conduction disturbances or other cardiac symptoms.
Clinical manifestations depend on the location and extent of granulomatous infiltration, being
the most common cause of cardiac involvement secondary to infiltration of the myocardium.
Usually, cardiac disease appears with any other organ involvement (lung, skin…). The most
frequent manifestations of cardiac sarcoidosis are heart failure and arrhythmias, produced in
both cases,by the infiltration of the myocardium.
5.3. Cardiac arrhythmias
The most common are ventricular arrhythmias, caused by infiltration of granulomas in the
ventricular myocardium causing a focus for abnormal automaticity, or a disruption of
ventricular activation and recover [100]. In patients with cardiac sarcoidosis, ventricular
arrhythimias and sudden death, due to ventricular tachycardia, are common causes of death.
Ventricular tachycardia is one of the most common manifestations of cardiac involvement,
being the 24-h ambulatory monitoring the best way to detect them. Supraventricular arrhyth‐
mias are infrequent.
5.4. Conduction abnormalities
Caused by the granulomatous infiltration at the atrioventricular node or bundle of His leading
to a first degree heart block. Initially, patients are usually asymptomatic but they can progress
to complete heart block [101].This can be detected by routine electrocardiography.
5.5. Heart failure
Caused by extensive granulomatous infiltration of the myocardium. May cause impairment
of systolic or diastolic function. Diagnostic is difficult and many patients with heart failure
due to sarcoidosis disease are diagnostic of idiopathic dilated cardiomyopathy.
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5.6. Other clinical manifestations
a. Valvular dysfunction: The most frequent is the involvement of the mitral valve caused by
diastolic dysfunction and left ventricular dilatation or granulomatous involvement of the
papillary muscle [102]. Less common is the tricuspid valve dysfunction.
b. Aorta aneurysm: Although are infrequent, has been described descending thoracic and
abdominal aorta aneurysm [103].
c. Cor pulmonale: May occur secondary to pulmonary fibrosis.
6. Gastrointestinal and liver sarcoidosis
6.1. Liver disease
Occurs in 13% of patients with systemic sarcoidosis [104]. Isolated liver involvement is
infrequent. In most cases there are no symptoms but can appear hepatosplenomegaly, elevated
liver enzymes, cholestasis or portal hypertension. In addition, 60% of patients with liver
disease have fever and / or concomitant arthralgia [104].
Although in most cases the granulomas in the liver are small and are located in the portal
space, symptoms consistent with chronic cholestasis [105] portal hypertension or Bud-Chiari
syndrome can appear [106] Intrahepatic cholestasis can resemble primary biliary cirrhosis or
sclerosing cholangitis.
Usually liver function is normal, but the most common abnormality is an elevation of alkaline
phosphatase level.
6.2. Gastrointestinal involvement
Affects less than 1% of patients with sarcoidosis, being the stomach the most affected organ of
the digestive tract. The symptoms of patients with gastric involvement are inespecific:
epigastric pain, heartburn, abdominal discomfort, nausea or vomiting, diarrhea and significant
weight loss.
Involvement of the intestine is very infrequent and can occasionally coexist with Crohn's
disease [107].
7. Neurosarcoidosis
Neurosarcoidosis is the neurologic manifestation of sarcoidosis, a system granulomatous
disease. The most affected organ is the lung, but it can also affect eyes, liver and nervous
system. It affects the 5-15% of patients with sarcoidosis. It can be manifested by a wide variety
of symptoms: peripheral neuropathy, central symptoms, loss of memory and behavior
changes. Psiquiatric manifestations include, but not exclusively, psychosis and delirium, with
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20% prevalence in patients with neurosarcoidosis or 1% in those affected with sarcoidosis. The
prevalence of neurosarcoidosis is similar to schizophrenia, between 0,50-1,46% of general
population. Thus, a study shows that 2 of each 268 patients with a first schizophrenia episode,
they had neurosarcoidosis.
Neurologic complications occur in approximately 5 percent of patients with sarcoidosis
[108-112]. Neurosarcoidosis is a diagnostic consideration in patients with known sarcoidosis
who develop neurologic complaints and in patients presenting de novo with a constellation
of findings consistent with the disease [113, 114]. About 50 percent of patients with neurosar‐
coidosis present with neurologic difficulties at the time of the diagnosis. One-third of those
with neurosarcoidosis has or develops more than one neurologic manifestation of their disease.
7.1. Clinical presentation
Any portion of the central or peripheral nervous system can be affected by sarcoidosis.
Neuropsychiatric: seizures, amnesia, psychosis and disorientation. Cranial mononeuropathy.
Peripheral facial nerve palsy develops in 25 to 50 percent of patients with neurosarcoidosis
[111, 114, 115]. The facial nerve palsy can be unilateral or bilateral (simultaneous or sequential)
and recurrent. Optic neuropathy and cranial nerve VIII dysfunction can lead to intermittent
or progressive visual, auditory, or vestibular dysfunction. Neuroendocrine dysfunction
typically occurs with hypothalamic inflammation, resulting in polyuria or disturbances in
thirst, sleep, appetite, temperature, or libido. Hypothalamic or pituitary lesions may also cause
thyroid, gonadal, or adrenal abnormalities [115, 117]. Polyuria can result from one or more
factors in patients with sarcoidosis. Direct hypothalamic involvement can lead to central
diabetes insipidus or primary polydipsia, while hyperkalemia (due to production of calcitriol
by activated macrophages) can cause nephrogenic diabetes insipidus [117]. Thus, all patients
with sarcoidosis and polyuria require a water restriction test to establish the correct diagnosis.
Granulomatous inflammation in a perivascular distribution can involve the brain and produce
partial or generalized seizures, or a restricted or generalized encephalopathy/vasculopathy
[114, 115]. Patients can present with cognitive or behavioral problems and/or focal neurologic
deficits referable to the anatomic area involved. In rare cases, this manifests as a focal cerebral
infarction [118]. A myelopathy or radiculopathy can occur if granulomatous inflammation
affects the spinal cord [114, 115, 119, 120]. The lesions are typically perivascular, they can be
extra medullary or intramedullary, and can involve the caudal equine. Communicating or no
communicating hydrocephalus may develop acutely or subacutely. Asymptomatic ventricular
enlargement may be incidentally detected by imaging studies. Sudden death can rarely result
from acute obstruction to CSF flow. Meningeal involvement can take the form of either acute
aseptic meningitis or chronic meningitis. Meningeal mass lesions also can develop. Peripheral
neuropathic presentations include a mononeuropathy, mononeuritis multiplex, and general‐
ized sensory, small fiber sensory, sensorimotor, autonomic and motor polyneuropathies [122].
The symptoms can be acute, subacute, or chronic; electromyography usually reveals an axonal
neuropathy. In addition, an acute generalized demyelinating motor neuropathy similar to the
Guillain-Barré syndrome also has been described [123]. Carpal tunnel syndrome appears to
be more common among patients with sarcoidosis than the general population [124-126].
Clinical Manifestations of Sarcoidosis
http://dx.doi.org/10.5772/55556
125
Muscle involvement includes asymptomatic microscopic nodules, isolated palpable nodules,
an acute or chronic proximal myopathy, and muscle atrophy [127].
In some series of patients affected with intracranial hypertension syndrome, whose manifes‐
tation is headache, the diagnosis is neurosarcoidosis. It is uncommon, however, it must be
include in differential diagnosis [109].
Patients presenting with neurosarcoidosis may have no systemic features of the disease. In one
case series, non-neurologic symptoms were present in less than one-fourth of patients and
were most commonly anterior uveitis, cough and dyspnea, renal impairment, rash, and
polyarthritis [114].
7.2. Diagnosis
Neurosarcoidosis is a diagnostic consideration in patients with known sarcoidosis who
develop neurologic findings, although an intercurrent infection or malignancy must be
excluded. Patients who develop a neurologic illness consistent with neurosarcoidosis but are
not known to have sarcoidosis present a diagnostic challenge. Table 5 summarizes findings in
patients with Neurosarcoidosis.
Findings in patients with Neurosarcoidosis Frequency (%)
Findings in Chest Rx 24-68%
Cranial mononeuropathy 25-50%
MRI meningeal enhancement 40%
Psychiatric symptoms 20%
Findings in Cerebrospinal fluid Frequency (%)
Elevated total protein 66%
Pleocytosis 50%
Elevated openning pressure 10%
Table 5. Findings in patients with Neurosarcoidosis
a. Clinical evaluation:
If neurosarcoidosis is suspected, the patient should be evaluated for evidence of extra neural
disease because obtaining nerve tissue for diagnostic evaluation is often difficult. Corticoste‐
roids can eliminate evidence of systemic inflammation, and the diagnostic evaluation should
be pursued in a rapid fashion while withholding immunosuppressive therapy unless severe
illness mandates its use.
The search for extra neural sarcoidosis should include a thorough evaluation of the skin, lymph
nodes, and lungs. Other tests that may be useful are:
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1. Ophthalmologic examination
2. Endoscopic nasal and sinus examination. A chest x-ray or computed tomographic scan
of  the  chest  to  look  for  hilar  adenopathy  or  parenchymal  changes  consistent  with
pulmonary sarcoidosis.  Positive findings suggestive of  sarcoidosis  on chest  imaging
have been reported in 24 to 68 percent  of  individuals  who present with neurologic
sarcoidosis [114, 115].
3. Serum angiotensin converting enzyme (ACE) assay, which may be helpful if elevated;
however, an elevated serum ACE is not specific for sarcoidosis, and the ACE concentration
may not necessarily be elevated if the patient has isolated neurosarcoidosis
4. In occasional cases, a magnetic resonance, gallium, or fluorodeoxyglucose positron
emission tomographic scan, may highlight otherwise occult areas of inflammation that
might be amenable to biopsy
b. Neurodiagnostic testing:
Neurologic evaluation should proceed if no extra neural tissue is available for biopsy.
Unfortunately, no neurodiagnostic tests are pathognomonic for neurosarcoidosis. However,
neurodiagnostic tests help define the extent of disease and eliminate other diagnostic consid‐
erations, particularly infection and malignancy. Furthermore, a presumptive diagnosis of
neurosarcoidosis is often made on the basis of MRI and lumbar puncture results in the
appropriate clinical setting [128].
c. Neuroimaging:
The imaging procedure of choice for CNS disease is contrast-enhanced MRI [115, 116, 129].
Meningeal or parenchymal enhancement suggests active inflammation with disruption of the
blood brain barrier, and parenchymal or meningeal masses and hydrocephalus are easily
identified. Involvement of the optic nerve or other cranial nerves can be documented, and
spinal cord and cauda equine inflammation is well seen on targeted images. Multiple paren‐
chymal nodules may actually represent inflammation extending along the Virchow-Robin
spaces deep into the brain or spinal cord. In one series of 29 patients with neurosarcoidosis,
approximately 40 percent demonstrated meningeal enhancement and/or multiple white
matter lesions on MRI [128].
d. Lumbar puncture:
Cerebrospinal fluid (CSF) abnormalities occur frequently in patients with CNS sarcoidosis
[114, 115]: The CSF opening pressure is elevated in approximately 10 percent of patients, and
the total protein is increased in two-thirds of patients, typically up to 250 mg/dL. A pleocytosis
is present in approximately 50 percent of patients. Glucose can be normal or low, as can be
seen in CNS infections or carcinomatous meningitis. A predominantly mononuclear cell
pleocytosis is common. The IgG index can be elevated, and oligoclonal bands may be present.
The CSF ACE concentration is occasionally elevated, but reliable normal values are lacking
and CSF ACE may also be increased with infection or carcinomatous meningitis.
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Caution should be applied in performing a LP in patients with neurosarcoidosis if there is
evidence of increased intracranial pressure. A funduscopic examination to exclude papillede‐
ma and an MRI to exclude ventricular enlargement, cerebral edema, and a mass lesion should
precede LP [130].
e. Other tests:
Other diagnostic tests, such as electroencephalography, evoked potentials, and angiography,
are occasionally indicated to exclude other conditions. Nerve conduction studies (NCS) and
electromyography (EMG) can help localize neuromuscular lesions, depending on the clinical
syndrome.
Although false-positive reactions to the Kveim-Siltzbach test are reported to be rare; the test
has limited utility [114]. The test is not standardized; it is not universally available; and there
are concerns regarding the transmission of HIV and hepatitis.
f. Biopsy:
If the diagnosis remains in doubt, meningeal, brain, or spinal cord biopsy is occasionally
indicated. Extra neural tissue biopsy from other clinically affected organs is generally pref‐
erable when possible, as it is less risky; skin, lymph node, and lung (trans bronchial) biopsies
can be of high yield [114, 115]. Muscle and peripheral nerve biopsy, including an epidermal
biopsy with quantitative nerve terminal analysis to document small fiber sensory neuropathy,
can all be easily performed for the appropriate syndrome.
8. Cutaneous manifestations of sarcoidosis
Cutaneous lesions of sarcoidosis may present with variety of morphologies [131]. Although
not life-threatening, the unsightly skin lesions of sarcoidosis can be emotionally devastating
[132]. Given the wide variability of clinical manifestations, it is one of the "great imitators,"
making it necessary to consider clinical, epidemiological, radiographic, laboratory, and
histopathological criteria to make the diagnosis [133]
Skin involvement is common (occurring in 25 to 35 % of patients with sarcoidosis). Cutaneous
manifestation of sarcoidosis could be one of the two following: specific lesions, which dem‐
onstrate granuloma on biopsy; and nonspecific lesions that do not have granulomas but are
inflammatory reactions [134].
Specific lesions are estimated to occur in 9 to 15 percent of patients with sarcoidosis. Although
their histopathologic features are similar, the clinical manifestations of specific lesions vary
widely [135]. Papules, nodules, plaques, and infiltrated scars are among the most common
presentations; other manifestations also occur.
8.1. Specific eruptions
a. Papular sarcoidosis
Papular sarcoidosis is a common specific cutaneous manifestation of sarcoidosis. Papular
sarcoidosis most frequently occurs on the face, with predilection for the eyelids and nasolabial
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folds. Upon resolution, faintly discolored, occasionally atrophic macules may remain at
previous sites of involvement [135, 136].
b. Nodular sarcoidosis
Nodular sarcoidosis is a relatively common form of cutaneous sarcoidosis that results from
large collections of sarcoidal granulomas in the dermis or subcutaneous tissue [135]. Nodules
tend to be between 1 and 2 cm in diameter and may be single or multiple. On the nose, nodular
sarcoidosis can resemble rhinophyma [135, 137]-
c. Maculopapular sarcoidosis
Characteristically, lesions are asymptomatic or pruritic, and consist of slightly infiltrated,
slightly hyperpigmented patches studded with slightly raised papules that are often around
1 mm in diameter [136]. Facial skin, especially the periorifial or eyelid area, is the most common
site of involvement.
d. Plaque sarcoidosis
Presents with oval or annular, indurated, discrete plaques that are flesh – colored, erythema‐
tous, or brown. Frequent site of involvement include the shoulders and arms, back, and
buttocks [131].
e. Lupus pernio
Lupus pernio is characterized by violaceous or erythematous indured papules, plaques, or
nodules that are primarily distributed on the central face [138]. The alar rim of the nose is often
affected. Lupus pernio is more common in women than in men and is associated with chronic
disease and extrapulmonary involvement [138, 139]. Without treatment, the lesions progres‐
sively increase in thickness, size, and induration, eventually resulting in considerable cosmetic
disfigurement.
The presence  of  lupus  pernio  appears  to  be  associated with  an increased risk  for  extra
cutaneous  disease,  particularly  sarcoidosis  involving  the  respiratory  tract  [140].  When
severe,  granulomatous  inflammation of  the  upper  respiratory  tract  can  result  in  airway
obstruction [141].
8.2. Non-Specific eruptions
a. Erythema nodosum
Erythema nodosum develops in up to 25 percent of patients with sarcoidosis and is clinically
and histologically identical to erythema nodosum secondary to other causes. García Porrúa et
al in Spanish study of 106 biopsy proven cases of erythema nodosum, 20 percent of patients
had sarcoidosis [142]. Arthritis, lower extremity edema, and low grave fever are the most
common systemic symptoms associated with erythema nodosum.
The clinical feature of subcutaneous sarcoidosis can resemble erythema nodosum. Biopsy is
useful for distinguishing between these disorders. Biopsy specimens of erythema nodosum
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lesions show nonspecific septal panniculitis, which neither confirms nor negates the diagnosis
of sarcoidosis [143].
b. Löfgren´s syndrome
Löfgren´s syndrome is an acute presentation of sarcoidosis characterized by the triad of hilar
adenopathy, erythema nodosum, and polyarthralgia or arthritis, with or without parenchymal
infiltrates or fever [132, 144]. The presence of bilateral hilar adenopathy and erythema
nodosum is usually, but no always, caused by acute sarcoidosis. More recently, the definition
has been expanded to include patients with hilar adenopathy and periarticular inflammation
with or without erythema nodosum [145].
8.3. Management of cutaneous sarcoidosis
a. First line agents:
Formal studies of local therapies for cutaneous sarcoidosis are limited, and the widespread
use of topical and intralesional corticosteroids for this disease primarily are based upon clinical
experience.
Topical corticosteroids: Superpotent topical corticosteroids are widely used for the treatment
of cutaneous sarcoidosis: Clobetasol, halobetasol.
Intralesional Corticosteroids: Generally accepted that intralesional injection of corticosteroids
can lead to flattening or resolution of cutaneous lesions: Triamcinolone
b. Seconds line agents
Systematic glucocorticoids (prednisone 20 to 40 mg/day)
Antimalarials: Hydroxychoroquine and chloroquine.
Methotrexate (10 to 25mg/week)
c. Refractory disease:
Patients who fail to respond to conventional first – and second – line therapies may benefit
from treatment with infliximab or thalidomide.
9. Sarcoid arthropathy
Arthritis is the most common musculoskeletal manifestation in sarcoidosis [146]. Approxi‐
mately 25 percent of patients with sarcoidosis have an associated arthropathy [147]. Real
incidence is unclear since the diagnosis may be difficult when a patient presents with articular
complaints alone; in this setting, the presence of sarcoidosis is established only after more
commonly involved organs, such as the eye or lung, become affected [148].
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9.1. Acute arthritis
Acute sarcoid arthritis may present in isolation or as part of Lofgren’s syndrome (association
of arthritis, erythema nodosum and bilateral hilar lymphadenopathy). Joint effusion is discrete
[149]. Rheumatoid factor and ANA may be positive, as in the general sarcoidosis [146]. The
acute polyarthritis most commonly involves ankles (>90 percent), often bilaterally, followed
by other larger joints of lower extremity and may be mistaken for a reactive arthritis. The
arthritis is mostly oligoarticular (87%), and involvement is typically symmetrical (76%).
Glennas et al, in a prospective study of 189 patients presenting with symptoms suggestive of
reactive arthritis, 17 (9%) were eventually diagnosed with acute sarcoid arthritis. Ten had
Löfgren´s syndrome, and 17 had bilateral ankle involvement [150].
Löfgren´s syndrome: The triad of hilar adenopathy, acute polyarthritis and erythema nodo‐
sum characterizes Löfgren´s syndrome. Löfgren´s syndrome is usually self-limiting. Erythema
nodosum typically disappears in a few months [144]. Approximately one third of patients have
persistent arthritis; rarely, the arthritis symptoms are recurrent. Hilar adenopathy tends to
resolve over time up to 90 percent of patients. Erythema nodosum is more often seen in female
compared with male patients presenting with Löfgren´s syndrome [142].
Sarcoid arthritis can resemble rheumatic fever when the polyarthritis is migratory. It may
resemble patients with juvenile idiopathic arthritis in young children presenting with both
uveitis and arthritis [151].
9.2. Chronic arthritis
Patients presenting with chronic arthritis are typically older than patients with acute arthritis
or Löfgren´s syndrome [144]. The ankle, knees, hands, wrist, metacarpophalangeal and
proximal interphalangeal joint are the joints most frequently involved; rarely, the sacroiliac
and temporomandibular joints may also be affected [144]. Chronic arthritis is frequently
associated with parenchymal lung disease and other extrapulmonary manifestations [144].
The correlation between extremely high serum of angiotensin converting enzyme levels and
extrathoracic sarcoidosis, including chronic arthritis, probably reflects the high total body load
of granulomas.
9.3. Diagnosis
Diagnosis of sarcoid arthropathy is based upon suggestive clinical, imaging, synovial fluid,
and, in selected cases, synovial tissue biopsy. Classic Löfgren´s syndrome can be diagnosed
based upon clinical features alone [132].
9.4. Treatment
Sarcoid arthritis should be treated with nonsteroidal antiinflammatory agents. Corticosteroids
and other immunosuppressive drugs as colchicine and hydroxychloroquine should be
reserved for refractory cases. Biological therapies such as the anti-TNFa and the anti-CD20
were showed to be effective in some case reports of severe and refractory disease [152].
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10. Ocular manifestations in sarcoidosis
The eye or adnexa are affected in 25 to 80% of the sarcoidosis patients. The disease can involve
the orbit, lacrimal gland, anterior and posterior segments of the eye [153].
The disease can involve the orbit,  lacrimal gland, anterior and posterior segments of the
eye. Anterior uveitis is the most common manifestation, occurring in 65% of patients with
ophthalmologic  involvement  [132].  Inflammation  can  affect  the  uveal  tract  leading  to
glaucoma, cataracts, and blindness. Typical sarcoid uveitis presents with bilateral mutton-
fat  keratic  precipitates,  cells,  flare,  iris  nodules,  anterior  and  posterior  synechia,  and
increased  ocular  pressure.  Posterior  involvement  includes  vitreitis,  vasculitis,  choroidal
lesions, and optic neuropathy. Long-term complications are common, and cystoid macu‐
lar  edema is  the  most  important  and sight-threatening consequence [153].  Acute  uveitis
presents  with  eye  redness,  cloudy  vision,  photophobia,  and  watering  or  can  present
asymptomatically (with a “quiet eye”).
The gold standard for the diagnosis of sarcoidosis should be obtained with histologic exami‐
nation. However, an international workshop has recently established diagnostic criteria of
"intraocular sarcoidosis" (sarcoidosis uveitis) on the basis of a combination of suggestive
ophthalmological findings and laboratory tests, when biopsy is not performed or is negative.
More recent techniques such as PET-scan and endoscopic ultrasound-guided fine-needle
biopsy of intrathoracic nodes should be assessed in future prospective studies [154].
Chronic anterior uveitis, with insidious symptoms leading to glaucoma and vision loss, is more
common than acute anterior uveitis. In about 10 to 15% of patients with uveitis, both the
anterior and posterior segments are involved.
Lacrimal  gland  enlargement  can  cause  dry  eyes.  Conjunctival  follicles,  dacryoscystitis,
keratoconjunctivitis sicca, and retinal vasculitis also occur. Optic neuritis is an ophthalmo‐
logic  emergency  that  requires  immediate  systemic  therapy  as  it  can  result  in  a  rapid
permanent loss of vision.
Papillitis,  papilledema,  and  neovascularization  are  seen  under  funduscopic  examination
leading to optic atrophy. Other less common manifestations include periphlebitis retinae,
retinal  hemorrhage,  retinitis  proliferans,  band keratopathy,  proptosis,  and exophthalmos
[155, 156].
Routine evaluation for eye involvement should include a slit-lamp examination and fundu‐
scopic examination to evaluate the anterior and posterior uveal tract, respectively [132].
Fluorescence angiography may also be considered if a posterior uveitis is suspected [156].
Oral corticosteroids are the mainstay of treatment of sarcoidosis. Systemic cytotoxic agents
like methotrexate, azathioprine, and chlorambucil may be used in refractory cases. The visual
prognosis of sarcoidosis is usually good [153].
Patients should be warned that skin atrophy could occur if steroids come into contact with
skin surfaces. Intraocular corticosteroid injections can provide the patient with longer control
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of symptoms. Systemic steroids can be used if uveitis does not resolve with topical therapy or
for cases where vision loss is possible. Alternative agents include tacrolimus, methotrexate,
and photodynamic therapy [157].
Minocycline may be an option for patients with comorbidities that make steroids a less
appealing option [158].
Interferon-alpha is commonly used to treat hepatitis C viral infection and has been reported
to induce sarcoidosis and more recently ocular sarcoidosis with granulomatous panuveitis
with choroidal granulomas.
In these cases topical steroids were used to treat ocular uveitis with systemic steroids for
systemic findings.
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